tirzepatide for weight loss approval is FDA-approved management, with clinical trials showing average weight of 15–22.5% over 72 weeks. It's a prescription-only therapy, meaning it's not for everyone, and it works by acting Tirzepatide for Weight Loss Receives

Biol Trace Elem Res 168(2):380391

Patient Assistance Program - Available Products

The most supportive approach is to follow the person's lead on whether they want to discuss their weight loss, avoid unsolicited comments about physical appearance, show interest in how they are feeling rather than how they look, and respond to expressions of anxiety about regain or body change with validation rather than reassurance-seeking behaviour

Hypothyroidism can develop with long-term HGH use as the hormone suppresses thyroid function

Much of the published work on it comes from animal and lab studies, not from large human trials

Implement structured taper